2815-95-4

Basic information

• Product Name: 3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID
• Synonyms: 1,3-BENZODIOXOLE-5-PROPANOIC ACID;3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID;3-(1,3-BENZODIOXOL-5-YL)PROPANOIC ACID;3,4-METHYLENEDIOXYDIHYDROCINNAMIC ACID;3,4-(METHYLENEDIOXY)HYDROCINNAMIC ACID;PIPERONYL ACETIC ACID;TIMTEC-BB SBB000324;3,4-(methylenedioxy)-hydrocinnamicaci
• CAS NO: 2815-95-4
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.18
• EINECS: 220-565-9
• Product Categories: Aromatic Propionic Acids;Aromatics;Heterocycles
• Mol File: 2815-95-4.mol
• Article Data: 29

Chemical Properties

• Melting Point: 86-88°C
• Boiling Point: 349℃
• Flash Point: 142℃
• Appearance: /
• Density: 1.343
• Vapor Pressure: 1.81E-05mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: Soluble in chloroform and ethyl acetate.
• PKA: 4.59±0.10(Predicted)
• BRN: 181735
• CAS DataBase Reference: 3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID(2815-95-4)
• EPA Substance Registry System: 3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID(2815-95-4)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• WGK Germany: 2
• RTECS: MW5600000
• HazardClass: IRRITANT
• Hazardous Substances Data: 2815-95-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID is used as an active pharmaceutical ingredient for its anti-inflammatory and analgesic properties. Its ability to reduce inflammation and alleviate pain makes it a valuable compound in the development of medications for various conditions, such as arthritis and other inflammatory diseases.
Used in Cosmetics Industry:
In the cosmetics industry, 3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID is used as an ingredient in skincare and anti-aging products due to its anti-inflammatory properties. It can help soothe irritated skin and reduce the appearance of fine lines and wrinkles, making it a popular choice for cosmetic formulations.
Used in Research and Development:
3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID is also used in research and development for its potential applications in various fields. Its chemical properties and biological activity make it an interesting compound for further study and potential development into new drugs or therapies.
Overall, 3-(3,4-METHYLENEDIOXYPHENYL)PROPIONIC ACID is a versatile compound with a range of applications in different industries, primarily due to its anti-inflammatory and analgesic properties. Its use in pharmaceuticals, cosmetics, and research highlights its potential for further development and utilization.

InChI:InChI=1/C10H10O4/c11-10(12)4-2-7-1-3-8-9(5-7)14-6-13-8/h1,3,5H,2,4,6H2,(H,11,12)/p-1

Upstream product

• 24393-66-6 ethyl (E)-3-(benzo[d][1,3]dioxol-5-yl)acrylate 
• 120-57-0 piperonal 
• 141-82-2 malonic acid 
• 143815-53-6 C₁₀H₈O₅ 
• 38243-40-2 β-(benzo[1,3]dioxol-5-yl)-α-acetamidoacrylic acid 
• 14731-78-3 ethyl 3,4-methylenedioxycinnamate 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 74402-06-5 2-benzo[1,3]dioxol-5-ylmethylmalonic acid dimethyl ester 
• 20850-43-5 5-(chloromethyl)-1,3-benzodioxole 
• 22180-30-9 Diethyl α-piperonylmalonate 
• 7315-32-4 5-vinyl-1,3-benzodioxole 
• 124-38-9 carbon dioxide 
• 1162198-85-7 (Z)-2-acetoxy-3-(3,4-methylenedioxyphenyl)acrylic acid 
• 7116-48-5 3-benzo[1,3]dioxol-5-yl-propionic acid ethyl ester 

Downstream Products

• 30830-55-8 3-(3,4-methylenedioxyphenyl)propionaldehyde 
• 6412-87-9 5,6-methylenedioxy-1-indanone 
• 647029-36-5 (2R)-1-hydroxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyn-3-one 
• 647029-45-6 (2S,3S)-2-Benzo[1,3]dioxol-5-ylmethyl-3-hydroxy-3-isopropyl-5-(4-methoxy-phenyl)-pent-4-ynal 
• 647029-29-6 5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyne-1,3-diol 
• 647029-41-2 5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyne-1,3-diol 
• 647029-28-5 5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyne-1,3-diol 
• 647008-05-7 (2R,3S)-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-3-(1-methylethyl)-4-pentyne-1,3-diol 
• 647029-39-8 (2S,3S)-3-hydroxy-3-isopropyl-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-4-pentynoic acid 
• 647029-34-3 (2R)-1-tert-butyldimethylsilyloxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyn-3-one 
• 647029-32-1 1-tert-butyldimethylsilyloxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyn-3-ol 
• 647029-40-1 (4S)-4-benzyl-[(2R,3S)-3-hydroxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-4-pentynoyl]-2-oxazolidinone 
• 647029-26-3 (4S)-4-benzyl-[(2R,3R)-3-hydroxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-4-pentynoyl]-2-oxazolidinone 
• 647029-27-4 (4S)-4-benzyl-[(2S,3S)-3-hydroxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-4-pentynoyl]-2-oxazolidinone 

Relevant articles and documents

Synthesis method and application of cubebin

The invention discloses a synthesis method of cubebin, which comprises the following steps: using 1,3-benzodioxole-5-carboxaldehyde and malonic acid as initial raw materials to generate 1,3-benzodioxole-5-propanoic acid, reacting the 1,3-benzodioxole-5-propanoic acid with oxalyl chloride to generate 1,3-benzodioxole-5-propionyl chloride, then reacting the 1,3-benzodioxole-5-propionyl chloride with (S)-4-benzyl-2-oxazolidinone to generate corresponding amide, reacting a product with bromopropyl to generate corresponding olefin, generating a corresponding carbonyl compound under the catalysis of a combined oxidant OsO4/NMO, using the carbonyl compound to prepare a corresponding hydroxyl compound, oxidizing the hydroxyl compound into a lactone compound by using a Fetizon reagent, reacting the lactone compound with 5-(bromomethyl)-1,3-benzodioxole, and finally, reducing the product by using diisobutylaluminium hydride to obtain cubebin. The invention further discloses application of cubebin in sedative and peaceful sleep. The invention provides a potential therapeutic drug for calming and sleeping.

Generalized Chemoselective Transfer Hydrogenation/Hydrodeuteration

A generalized, simple and efficient transfer hydrogenation of unsaturated bonds has been developed using HBPin and various proton reagents as hydrogen sources. The substrates, including alkenes, alkynes, aromatic heterocycles, aldehydes, ketones, imines, azo, nitro, epoxy and nitrile compounds, are all applied to this catalytic system. Various groups, which cannot survive under the Pd/C/H2 combination, are tolerated. The activity of the reactants was studied and the trends are as follows: styrene'diphenylmethanimine'benzaldehyde'azobenzene'nitrobenzene'quinoline'acetophenone'benzonitrile. Substrates bearing two or more different unsaturated bonds were also investigated and transfer hydrogenation occurred with excellent chemoselectivity. Nano-palladium catalyst in situ generated from Pd(OAc)2 and HBPin extremely improved the TH efficiency. Furthermore, chemoselective anti-Markovnikov hydrodeuteration of terminal aromatic olefins was achieved using D2O and HBPin via in situ HD generation and discrimination. (Figure presented.).

Design, synthesis, trypanocidal activity, and studies on human albumin interaction of novel s-alkyl-1,2,4-triazoles

Chagas disease is a neglected tropical disease caused by the hemoflagellated parasite Trypanosoma cruzi (Kinetoplastida). The only available drug to treat chagasic patients in Brazil, the nitroheterocycle benznidazole, is effective solely during the acute phase of the infection. There is accordingly a need to develop new therapeutic tools for the treatment of Chagas disease. This work reports the synthesis, trypanocidal evaluation and human serum albumin (HSA) interactions of a novel series of 1,2,4-triazoles. The new derivatives were synthesized via microwave irradiation in good yields. Most compounds showed toxic effects against T. cruzi with low toxicity to host cells. Three S-alkylated-triazoles showed the best activity profile against amastigotes, with half maximal inhibitory concentration (IC50) values of 3.95 ± 1.41, 4.15 ± 0.92 and 3.61 ± 0.65 μmol L-1, respectively. The interaction between HSA and 3-[(1E,3E)-4-(1,3-benzodioxol-5-yl)buta-1,3-dien-1-yl]-5-(butylthio)-4-cyclohexyl-4,5-dihydro-1H-1,2,4-triazole was investigated using multiple spectroscopic techniques and molecular docking, revealing that serum albumin is a potential endogenous carrier to this compound in the human bloodstream.

COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Total Synthesis and Evaluation of B-Homo Palmatine and Berberine Derivatives as p300 Histone Acetyltransferase Inhibitors

Palmatine and berberine, structurally similar isoquinoline alkaloids exhibiting a broad range of biological activities, were recently found to inhibit p300 histone acetyltransferase (HAT), a potential therapeutic target for treating transcriptional activator-driven malignancies and diseases. Here, we report the first total synthesis of B-homo palmatine (11a) and berberine (11b) derivatives, which were synthesized from 3,4-dimethoxybenzaldehyde (1a) and benzo[d][1,3]dioxole-5-carbaldehyde (1b) in nine steps in 13.8 and 16.9 % overall yields, respectively. A number of other new B-homo palmatine and berberine derivatives were also prepared. These derivatives display good inhibitory activity against p300 HAT; compound 12a manifests the most potent inhibition with an IC50 value of 0.42 μm. Cell-based assays revealed that 12a exhibits certain inhibitory activity against HCG27, HT1080, and Z-138 cell lines, and no visible activity towards other cancer cell lines tested, reflecting that 12a has low cytotoxicity and acts against some types of cancer cells.

High B ring berberine and palmatine derivative synthesis and as the use of reducing blood sugar (by machine translation)

The present invention provides a new class of high B ring berberine and palmatine derivative, as shown in the structural formula is shown as: The invention also provides a high B ring berberine and palmatine derivative of preparation and use. The potency test Certificate, the compounds of the invention having good in-vitro hypoglycemic effect, part of the superior to the berberine hydrochloride positive control. The invention high B ring berberine and palmatine derivative potency is prominent, there may be clinical provides a new choice of drug use for. (by machine translation)

Modular synthesis and biological investigation of 5-hydroxymethyl dibenzyl butyrolactones and related lignans

Dibenzyl butyrolactone lignans are well known for their excellent biological properties, particularly for their notable anti-proliferative activities. Herein we report a novel, efficient, convergent synthesis of dibenzyl butyrolactone lignans utilizing the acyl-Claisen rearrangement to stereoselectively prepare a key intermediate. The reported synthetic route enables the modification of these lignans to give rise to 5-hydroxymethyl derivatives of these lignans. The biological activities of these analogues were assessed, with derivatives showing an excellent cytotoxic profile which resulted in programmed cell death of Jurkat T-leukemia cells with less than 2% of the incubated cells entering a necrotic cell death pathway.

Total syntheses of surinone B, alatanones A–B, and trineurone A

The total syntheses of four polyketides, surinone B (1), alatanones A–B (2–3), and trineurone A (4) were accomplished through an efficient and unified strategy via one-pot C-acylation reaction coupling 1,3-cyclohexadiones with EDC-activated acids under mild conditions. Alatanone A (2) was found to be a potent anti-microbial agent against Gram-positive and Gram-negative bacteria with MIC 31.25?μg/ml while alatanone B (3) was found to be a potent anti-fungal agent against Cladosporium cladosporioides with MIC 62.5?μg/ml compared to cycloheximide MIC 125?μg/ml. Our methodology allows performing kilogram scale of these scarce polyketides for the development of new antimicrobials.

A berberine of the preparation method of the key intermediate

The invention discloses a preparation method of a key intermediate of berberine. The method comprises the following steps: enabling pepper benzyl chloride to react with malonic acid diester under the action of organic alkali, so as to obtain pepper diester benzylmalonate; carrying out decarboxylation on the pepper diester benzylmalonate under the catalysis of strong alkali; enabling pepper propionic acid to react with phosphorus pentachloride in an organic solvent, so as to obtain pepper propionyl chloride; enabling pepper propionyl chloride to react with ammonia gas or ammonia water in the organic solvent, so as to obtain pepper propanamide; and carrying out Hoffman rearrangement reaction on propanamide under the common action of sodium hypochlorite or chlorine gas or sodium hydroxide, so as to obtain the pepper ethylamine. According to the method disclosed by the invention, raw materials are available, the operation is simple, the reaction condition is mild, and industrial production can be achieved easily.

Direct β-Selective Hydrocarboxylation of Styrenes with CO2 Enabled by Continuous Flow Photoredox Catalysis

The direct β-selective hydrocarboxylation of styrenes under atmospheric pressure of CO2 has been developed using photoredox catalysis in continuous flow. The scope of this methodology was demonstrated with a range of functionalized terminal styrenes, as well as α-substituted and β-substituted styrenes.